Primary source: Inspections and Compliance
The FDA approved Mimrylo (rusfertide) on August 28, 2026, for the treatment of adults with polycythemia vera, marking the first novel therapy for this condition.
This approval offers a new treatment option that could greatly reduce the burden of disease management for patients and decrease the need for frequent blood draws, improving patient quality of life.
Labeling and risk management updates are required to reflect the new drug approval, including the incorporation of safety and efficacy data from the VERIFY trial.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Labeling and risk management updates are required to reflect the new drug approval, including the incorporation of safety and efficacy data from the VERIFY trial.
Mimrylo is a new treatment approved by the FDA for adults with polycythemia vera, a condition causing excess red blood cells. This first-in-class drug mimics hepcidin to limit iron available for red blood cell production and was shown to significantly reduce reliance on phlebotomy.
What changed: The FDA approved Mimrylo (rusfertide) on August 28, 2026, for the treatment of adults with polycythemia vera, marking the first novel therapy for this condition.
Why it matters: This approval offers a new treatment option that could greatly reduce the burden of disease management for patients and decrease the need for frequent blood draws, improving patient quality of life.
Practical implication: Labeling and risk management updates are required to reflect the new drug approval, including the incorporation of safety and efficacy data from the VERIFY trial.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitor and evaluate the drug misuse trends and health impacts associated with ketamine, focusing on the increase in seizures as part of public health and law enforcement strategies.
Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.
Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.
The marketing authorization holder must submit amended product information reflecting the new safety guidelines by October 9, 2026, with translations due by August 10, 2026.
